|67.05||+4.14||+6.58%||Vol 408.54K||1Y Perf -44.23%|
|Apr 8th, 2020 16:00|
|- -%||- -%|
|Target Price||151.56||Analyst Rating||Strong Buy 1.40|
|Potential %||126.04||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-68||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-100/-26||Growth Ranking||★+ 41.60|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-7||Income Ranking||— -|
|Market Cap||2.20B||Earnings Rating||Sell|
|Price Range Ratio 52W %||25.16||Earnings Date||13th May 2020|
Today's Price Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
Return on Equity (5Y Avg)
ROE last 12 Months
Return on Assets (5Y Avg)
ROA last 12 Months
Return on Capital (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||13th May 2020|
|Estimated EPS Next Report||-2.83|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||494.53K|
|Avg. Monthly Volume||665.70K|
|Avg. Quarterly Volume||589.55K|
Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) closed at 67.05 per share at the end of the most recent trading day (a 6.58% change compared to the prior day closing price) with a volume of 463.42K shares and market capitalization of 2.20B. Is a component of indexes and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 483 people. Intercept Pharmaceuticals Inc. CEO is Mark Pruzanski.
The one-year performance of Intercept Pharmaceuticals Inc. stock is -44.23%, while year-to-date (YTD) performance is -45.89%. ICPT stock has a five-year performance of -75.33%. Its 52-week range is between 47.57 and 125, which gives ICPT stock a 52-week price range ratio of 25.16%
Intercept Pharmaceuticals Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 37.44, a price-to-sale (PS) ratio of 10.34, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -55.06%, a ROC of -61.51% and a ROE of -981.52%. The company’s profit margin is -%, its EBITDA margin is -119.00%, and its revenue ttm is $199.75 Million , which makes it $6.08 revenue per share.
Of the last four earnings reports from Intercept Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-2.83 for the next earnings report. Intercept Pharmaceuticals Inc.’s next earnings report date is 13th May 2020.
The consensus rating of Wall Street analysts for Intercept Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $151.56, which is +126.04% compared to the current price. The earnings rating for Intercept Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Intercept Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Intercept Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 33.99, ATR14 : 6.19, CCI20 : 83.04, Chaikin Money Flow : -0.06, MACD : -4.70, Money Flow Index : 66.81, ROC : 15.52, RSI : 48.63, STOCH (14,3) : 79.04, STOCH RSI : 1.00, UO : 48.28, Williams %R : -20.96), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Intercept Pharmaceuticals Inc. in the last 12-months were: Christian Weyer (Sold 0 shares of value $-395 885 ), Christian Weyer (Sold 11 028 shares of value $1 097 793 ), David A. Ford (Sold 858 shares of value $60 060 ), David Shapiro (Sold 0 shares of value $-255 200 ), David Shapiro (Sold 8 000 shares of value $725 120 ), Gail Cawkwell (Sold 0 shares of value $-117 236 ), Gail Cawkwell (Sold 316 shares of value $39 500 ), Jason Campagna (Sold 886 shares of value $101 126 ), Lisa Bright (Sold 1 785 shares of value $138 230 ), Luca Benatti (Buy at a value of $100 200), Mark Pruzanski (Sold 0 shares of value $-644 098 ), Mark Pruzanski (Sold 50 517 shares of value $5 064 625 ), Paolo Fundaro (Sold 0 shares of value $-102 887 ), Ryan T. Sullivan (Sold 0 shares of value $-471 343 ), Ryan T. Sullivan (Sold 12 654 shares of value $1 075 590 ), Srinivas Akkaraju (Buy at a value of $4 812 663), Srinivas Akkaraju (Sold 0 shares of value $-85 660 )
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.